Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~A patient must meet all of the following inclusion criteria to be eligible for participation in this study:~* Chronic hepatitis B virus (HBV) infection, defined as positive serum hepatitis B s-antigen (HBsAg) for more than 6 months~* 18 through 69 years of age, inclusive~* Active hepatitis B e-antigen (HBeAg) positive chronic HBV infection, with all of the following:~  * HBeAg positive at screening~ * Alanine aminotransferase (ALT) levels \> 2 × ULN and ≤ 10 × the upper limit of the normal range (ULN)~ * Serum HBV DNA \> 1 million copies/mL at screening~ * creatinine clearance ≥ 70 mL/min~ * hemoglobin ≥ 8 g/dL~ * neutrophils ≥ 1,000 /mL~* Knodell necroinflammatory score ≥ 3 and a Knodell fibrosis score \< 4; however, up to 96 patients with cirrhosis, ie, a Knodell fibrosis score equal to 4, will be eligible for enrollment~* Negative serum β-human chorionic gonadotropin (hCG)~* Nucleotide naïve, ie, no prior nucleotide (TDF or ADV) therapy for \> 12 weeks~* Nucleoside naïve, ie, no prior nucleoside (any nucleoside) therapy for \> 12 weeks~* Willing and able to provide written informed consent~* Liver biopsy performed within 6 months of baseline and has readable biopsy slides or agrees to have a biopsy performed prior to baseline~Key Exclusion Criteria:~A patient who meets any of the following exclusion criteria is not to be enrolled in this study:~* Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study~* Males and females of reproductive potential who are unwilling to use an effective method of contraception during the study; for males, condoms should be used and for females, a barrier contraception method should be used~* Decompensated liver disease defined as conjugated bilirubin \> 1.5 x ULN, prothrombin time (PT) \> 1.5 x ULN, platelets \< 75,000/mL, serum albumin \< 3.0 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage)~* Received any nucleoside, nucleotide (TDF or ADV) or interferon (pegylated or not) therapy within 6 months prior to the pre-treatment biopsy~* Evidence of hepatocellular carcinoma (HCC), ie, α-fetoprotein \>50 ng/mL~* Coinfection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or hepatitis delta virus (HDV)~* Significant renal, cardiovascular, pulmonary, or neurological disease~* Received solid organ or bone marrow transplantation~* Is currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion~* Has proximal tubulopathy~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- TDF-TDF (Type: EXPERIMENTAL): TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.
- ADV-TDF (Type: ACTIVE_COMPARATOR): ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.

Based on this trial design, predict the completion outcome and termination type (if applicable).